MedTrace Logo

A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

NCT03977649 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2021-08-13

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of erenumab on central sensitization and brain networks connectivity of migraine patients

Conditions

  • Migraine Disorders

Interventions

DRUG

erenumab

erenumab 140 mg sc every 4 weeks

DRUG

placebo

placebo sc every 4 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-30
Primary Completion
2021-07-05
Completion
2021-07-05
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03977649 on ClinicalTrials.gov